A Phase I Study to Evaluate the Safety and Efficacy of PSMA-CART Co-expressing LIGHT in Treating Patients With Castrate-Resistant Prostate Cancer (CRPC)

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Anti PSMA chimeric antigen receptor T cell therapy BRL Medicine (Primary) ; Cyclophosphamide; Fludarabine
Indications Prostate cancer
Focus Adverse reactions
Sponsors BRL Medicine

04 Jan 2024 Planned End Date changed from 30 Dec 2023 to 15 Oct 2024.
25 Jan 2023 Planned primary completion date changed from 15 Nov 2022 to 15 Nov 2023.
02 Apr 2022 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com